CareDx agreed to acquire Naveris for up to $260 million, extending its precision oncology footprint with viral-driven liquid biopsy monitoring. The acquisition targets NavDx, a test designed to measure circulating HPV DNA fragments to support detection and disease management in HPV-related cancers. CareDx highlighted that NavDx received Medicare coverage in 2023 and is intended for longitudinal monitoring within specialty workflows. The company also noted Naveris operates high-complexity clinical laboratories and has completed more than 130,000 commercial tests. Strategically, the deal positions CareDx to deepen exposure to MRD-style surveillance in settings where longitudinal molecular monitoring is already reimbursed, while enabling future validation work in additional tumor types.